Metuzumab, a chimeric antibody, and I131-metuximab, a murine anti-CD147 antibody labeled with radioactive iodine (I131), have demonstrated potential in esophageal cancer and HCC, respectively, by inhibiting tumor growth and metastasis [23,24]. Here, BSG is linked to hepatocellular carcinoma.